100511-78-2

Basic information

• Product Name: Methyl 3-[4-(aminomethyl)phenyl]propionate
• Synonyms: methyl 3-(4-aminomethylphenyl)propanoate;Methyl 3-[4-(aminomethyl)phenyl]propionate;3-(4-Aminomethylphenyl)propionic acid methyl ester;Benzenepropanoic acid, 4-(aMinoMethyl)-, Methyl ester
• CAS NO: 100511-78-2
• Molecular Formula: C₁₁H₁₅NO₂
• Molecular Weight: 193.24
• Product Categories: Aminomethyl's;Phenyls & Phenyl-Het
• Mol File: 100511-78-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 299.4 °C at 760 mmHg
• Flash Point: 155 °C
• Appearance: /
• Density: 1.081 g/cm³
• Vapor Pressure: 0.0012mmHg at 25°C
• Refractive Index: 1.53
• PKA: 9.13±0.10(Predicted)
• CAS DataBase Reference: Methyl 3-[4-(aminomethyl)phenyl]propionate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-[4-(aminomethyl)phenyl]propionate(100511-78-2)
• EPA Substance Registry System: Methyl 3-[4-(aminomethyl)phenyl]propionate(100511-78-2)

Safety Data

• Hazardous Substances Data: 100511-78-2(Hazardous Substances Data)

Usage

General Description

Methyl 3-[4-(aminomethyl)phenyl]propionate, also known as MAP, is a chemical compound used in the production of various pharmaceuticals and industrial products. It is classified as an ester, with a chemical structure that includes a methyl group, a benzene ring, and an amino functional group. MAP is commonly used as an intermediate in the synthesis of active pharmaceutical ingredients, such as antihistamines and analgesics. Its properties make it suitable for use in the manufacture of fragrances, flavors, and other specialty chemicals. The compound is also valued for its ability to react with other chemicals in a controlled manner, making it a versatile building block in organic chemistry and drug development.

InChI:InChI=1/C11H15NO2/c1-14-11(13)7-6-9-2-4-10(8-12)5-3-9/h2-5H,6-8,12H2,1H3

Upstream product

• 67472-79-1 methyl 3-(4-cyanophenyl)propenoate 
• 1643-30-7 3-(4-bromophenyl)propionic acid 
• 75567-84-9 methyl 3-(4-bromopehynl)propanoate 
• 75567-85-0 3-(p-Cyanophenyl)-propansaeuremethylester 
• 42287-94-5 (4-cyanophenyl)propionic acid 
• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 132691-44-2 methyl 4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]benzenepropanoate 
• 3959-07-7 4-Bromobenzylamine 

Downstream Products

• 61629-79-6 β-[4-(5-chloro-2-methoxybenzamidomethyl)-phenyl]-propionic acid 
• 132691-45-3 3-[4-[(tert.Butyloxycarbonylamino)methyl]phenyl]propionic acid 
• 561300-75-2 N-[4-(2-methoxycarbonyl-ethyl)-phenylmethyl]-4-(4'-trifluoromethyl-biphenyl-2-carbonylamino)-1-methyl-pyrrole-2-carboxylic acid amide 

Relevant articles and documents

Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists

GSK805 (1) is a potent RORγt inverse agonist, but a drawback of 1 is its low solubility, leading to a limited absorption in high doses. We have explored detailed structure-activity relationship on the amide linker, biaryl and arylsulfonyl moieties of 1 trying to improve solubility while maintaining RORγt activity. As a result, a novel series of carboxyl-containing biaryl urea derivatives was discovered as potent RORγt inverse agonists with improved drug-like properties. Compound 3i showed potent RORγt inhibitory activity and subtype selectivity with an IC50 of 63.8 nM in RORγ FRET assay and 85 nM in cell-based RORγ-GAL4 promotor reporter assay. Reasonable inhibitory activity of 3i was also achieved in mouse Th17 cell differentiation assay (76percent inhibition at 0.3 μM). Moreover, 3i had greatly improved aqueous solubility at pH 7.4 compared to 1, exhibited decent mouse PK profile and demonstrated some in vivo efficacy in an imiquimod-induced psoriasis mice model.

Preparation of phenylethylbenzamide derivatives as modulators of DNMT3 activity

DNA-methyltransferases (DNMTs) are a class of epigenetic enzymes that catalyze the transfer of a methyl moiety from the methyl donor S-adenosyl-l-methionine onto the C5 position of cytosine in DNA. This process is dysregulated in cancers and leads to the hypermethylation and silencing of tumor suppressor genes. The development of potent and selective inhibitors of DNMTs is of utmost importance for the discovery of new therapies for the treatment of cancer. We report herein the synthesis and DNMT inhibitory activity of 29 analogues derived from NSC 319745. The effect of selected compounds on the methylation level in the MDA-MB-231 human breast cancer cell line was evaluated using a luminometric methylation assay. Molecular docking studies have been conducted to propose a binding mode for this series.

Spergualin-related compounds having a phenylene group as well as a process for producing the same

The invention relates to Spergualin-related compounds of the formula: STR1 (wherein R1 is a lower alkylene group which may be substituted by a hydroxymethyl group; X is a hydrogen atom or a halogen atom; m and n are each 0 or an integer of 1 to